| Peer-Reviewed

DKK1 Promoter Methylation in Colorectal Cancer Is Associated with CIMP and Elevation of MYC Expression

Received: 11 April 2022    Accepted: 3 May 2022    Published: 12 May 2022
Views:       Downloads:
Abstract

Background: Carcinogenesis of colorectal cancer (CRC) is influenced greatly by the canonical WNT signaling pathway. Genetically, the secreted protein Dickkopf (Dkk) family is known as an antagonist to the WNT. To clarify the role of DKK1 in the WNT signaling pathway in the colorectal carcinogenesis, we examined the DKK1 promoter methylation in CRC and analyze the relationship of expression level of DKK1 and MYC in relation with APC gene abnormalities. Methods: We integrated clinico-pathological and molecular findings of 41 cases of CRC. We adopted methylation-specific PCR, DNA sequencing, allelic loss analysis, quantitative RT-PCR, and MSI testing for genetic analyses. Results: CRCs with DKK1 promotor methylation were found in 10 cases (24.4%), which were located predominantly in the proximal colon and frequently showed findings of poorly differentiated adenocarcinoma or mucinous adenocarcinoma. Furthermore, colorectal cancers with DKK1 promotor methylation showed characteristics of microsatellite instability (MSI)-high (70%) and a BRAF mutation (40%), which are known as the CpG island methylator phenotype (CIMP). In the DKK1 promotor methylation group, the relative expression level of DKK1 mRNA was significantly reduced in comparison to the DKK1 promotor un-methylation group (p < 0.05). When excluding the impact of APC abnormality, MYC expression in the DKK1 promotor methylation group was significantly elevated compared to that in the DKK1 promotor un-methylation group (p < 0.05). Conclusions: It is suggested that DKK1 is one of the regulators involved in MYC expression through the WNT signaling pathway and may have a negative effect on carcinogenesis of the colorectum without APC abnormalities.

Published in International Journal of Gastroenterology (Volume 6, Issue 1)
DOI 10.11648/j.ijg.20220601.13
Page(s) 9-17
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

DKK1, MYC, WNT Signaling Pathway, Methylation, Colorectal Cancer, CIMP

References
[1] Tamura, K., Utsunomiya, J., Iwama, T., et al. (2004). Mechanism of carcinogenesis in familial tumors. Int J Clin Oncol 9 (4), 232-245. doi: 10.1007/s10147-004-0430-4.
[2] Lengauer, C., Kinzler, K. W., Vogelstein, B. (1997). DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 94 (6), 2545-250. doi: 10.1073/pnas.94.6.2545.
[3] Vogelstein, B., Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nat Med 10 (8), 789-799. doi: 10.1038/nm1087.
[4] Matsubara, N. (2012). Epigenetic regulation and colorectal cancer. Dis Colon Rectum 55 (1), 96-104. doi: 10.1097/DCR.0b013e318233a1ef.
[5] Komiya, Y., Habas, R. (2008). Wnt signal transduction pathways. Organogenesis 4 (2), 68-75. doi: 10.4161/org.4.2.5851.
[6] Niehrs, C. (2006). Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25 (57), 7469-7481. doi: 10.1038/sj.onc.1210054.
[7] Cselenyi, C. S., Lee, E. (2008). Context-dependent activation or inhibition of Wnt-beta-catenin signaling by Kremen. Sci Signal 1 (8), pe10, 2008. doi: 10.1126/stke.18pe10.
[8] Aguilera, O., Fraga, M. F., Ballestar, E., et al. (2006). Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25 (29), 4116-4121. doi: 10.1038/sj.onc.1209439.
[9] Maehata, T., Taniguchi, H., Yamamoto, H., et al. (2008). Transcriptional silencing of Dickkopf gene family by CpG island hypermethylation in human gastrointestinal cancer. World J Gastroenterol 14 (17), 2702-2714. doi: 10.3748/wjg.14.2702.
[10] Rawson, J. B., Manno, M., Mrkonjic, M., et al. (2011) Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis 32 (5), 741-747. doi: 10.1093/carcin/bgr020.
[11] He, T. C., Sparks, A. B., Rago, C., et al. (1998). Identification of c-MYC as a target of the APC pathway. Science 281 (5382), 1509-1512. doi: 10.1126/science.281.5382.1509.
[12] Wilkins, J. A., Sansom, O. J. (2008). C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res 68 (13), 4963-4966. doi: 10.1158/0008-5472.CAN-07-5558.
[13] Kuno, T., Matsubara, N., Tsuda, S., et al. (2012). Alteration of the base excision repair gene MUTYH in sporadic colorectal cancer. Oncol Rep 28 (2), 473-480. doi: 10.3892/or.2012.1836.
[14] Boland, C. R., Thibodeau, S. N., Hamilton, S. R., et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (22), 5248-5257.
[15] Sato, H., Suzuki, H., Toyota, M., et al. (2007). Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 28 (12), 2459-2466. doi: 10.1093/carcin/bgm178.
[16] The Cancer Genome Atlas Network. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (7407), 330-337. doi: 10.1038/nature11252.
[17] Toyota, M., Ahuja, N., Ohe-Toyota, M., et al. (1999). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96 (15), 8681-8686. doi: 10.1073/pnas.96.15.8681.
[18] Weisenberger, D. J., Siegmund, K. D., Campan, M., et al. (2006). CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38 (7), 787-793. doi: 10.1038/ng1834.
[19] Jass, J. R. (2007). Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50 (1), 113-130. doi: 10.1111/j.1365-2559.2006.02549.x.
[20] Phipps, A. I., Limburg, P. J., Baron, J. A., et al. (2015). Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterol 48 (1), 77-87. doi: 10.1053/j.gastro.2014.09.038.
[21] Carethers, J. M., Jung, B. H. (2015). Genetics and Genetic biomarkers in sporadic colorectal cancer. Gastroenterol 149 (5), 1177-1190. doi: 10.1053/j.gastro.2015.06.047.
[22] Sargent, D. J., Marsoni, S., Monges, G., et al. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28 (20), 3219-3226. doi: 10.1200/JCO.2009.27.1825.
[23] Jover, R., Nguyen, T. P., Pérez-Carbonell, L., et al. (2011). 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterol 140 (4), 1174-1181. doi: 10.1053/j.gastro.2010.12.035.
[24] Le, D. T., Uram, J. N., Wang, H., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (26), 2509-2520. doi: 10.1056/NEJMoa1500596.
[25] Fearon, E. R., Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61 (5), 759-767. doi: 10.1016/0092-8674(90)90186-i.
Cite This Article
  • APA Style

    Mie Yoshimura, Kazuo Tamura, Tomoki Yamano, Nagahide Matsubara, Akihito Babaya, et al. (2022). DKK1 Promoter Methylation in Colorectal Cancer Is Associated with CIMP and Elevation of MYC Expression. International Journal of Gastroenterology, 6(1), 9-17. https://doi.org/10.11648/j.ijg.20220601.13

    Copy | Download

    ACS Style

    Mie Yoshimura; Kazuo Tamura; Tomoki Yamano; Nagahide Matsubara; Akihito Babaya, et al. DKK1 Promoter Methylation in Colorectal Cancer Is Associated with CIMP and Elevation of MYC Expression. Int. J. Gastroenterol. 2022, 6(1), 9-17. doi: 10.11648/j.ijg.20220601.13

    Copy | Download

    AMA Style

    Mie Yoshimura, Kazuo Tamura, Tomoki Yamano, Nagahide Matsubara, Akihito Babaya, et al. DKK1 Promoter Methylation in Colorectal Cancer Is Associated with CIMP and Elevation of MYC Expression. Int J Gastroenterol. 2022;6(1):9-17. doi: 10.11648/j.ijg.20220601.13

    Copy | Download

  • @article{10.11648/j.ijg.20220601.13,
      author = {Mie Yoshimura and Kazuo Tamura and Tomoki Yamano and Nagahide Matsubara and Akihito Babaya and Michiko Yasuhara and Aya Yano and Miki Fukumoto and Norihito Kawashita and Junko Tatsumi-Miyajima and Naohiro Tomita},
      title = {DKK1 Promoter Methylation in Colorectal Cancer Is Associated with CIMP and Elevation of MYC Expression},
      journal = {International Journal of Gastroenterology},
      volume = {6},
      number = {1},
      pages = {9-17},
      doi = {10.11648/j.ijg.20220601.13},
      url = {https://doi.org/10.11648/j.ijg.20220601.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijg.20220601.13},
      abstract = {Background: Carcinogenesis of colorectal cancer (CRC) is influenced greatly by the canonical WNT signaling pathway. Genetically, the secreted protein Dickkopf (Dkk) family is known as an antagonist to the WNT. To clarify the role of DKK1 in the WNT signaling pathway in the colorectal carcinogenesis, we examined the DKK1 promoter methylation in CRC and analyze the relationship of expression level of DKK1 and MYC in relation with APC gene abnormalities. Methods: We integrated clinico-pathological and molecular findings of 41 cases of CRC. We adopted methylation-specific PCR, DNA sequencing, allelic loss analysis, quantitative RT-PCR, and MSI testing for genetic analyses. Results: CRCs with DKK1 promotor methylation were found in 10 cases (24.4%), which were located predominantly in the proximal colon and frequently showed findings of poorly differentiated adenocarcinoma or mucinous adenocarcinoma. Furthermore, colorectal cancers with DKK1 promotor methylation showed characteristics of microsatellite instability (MSI)-high (70%) and a BRAF mutation (40%), which are known as the CpG island methylator phenotype (CIMP). In the DKK1 promotor methylation group, the relative expression level of DKK1 mRNA was significantly reduced in comparison to the DKK1 promotor un-methylation group (p MYC expression in the DKK1 promotor methylation group was significantly elevated compared to that in the DKK1 promotor un-methylation group (p Conclusions: It is suggested that DKK1 is one of the regulators involved in MYC expression through the WNT signaling pathway and may have a negative effect on carcinogenesis of the colorectum without APC abnormalities.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - DKK1 Promoter Methylation in Colorectal Cancer Is Associated with CIMP and Elevation of MYC Expression
    AU  - Mie Yoshimura
    AU  - Kazuo Tamura
    AU  - Tomoki Yamano
    AU  - Nagahide Matsubara
    AU  - Akihito Babaya
    AU  - Michiko Yasuhara
    AU  - Aya Yano
    AU  - Miki Fukumoto
    AU  - Norihito Kawashita
    AU  - Junko Tatsumi-Miyajima
    AU  - Naohiro Tomita
    Y1  - 2022/05/12
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ijg.20220601.13
    DO  - 10.11648/j.ijg.20220601.13
    T2  - International Journal of Gastroenterology
    JF  - International Journal of Gastroenterology
    JO  - International Journal of Gastroenterology
    SP  - 9
    EP  - 17
    PB  - Science Publishing Group
    SN  - 2640-169X
    UR  - https://doi.org/10.11648/j.ijg.20220601.13
    AB  - Background: Carcinogenesis of colorectal cancer (CRC) is influenced greatly by the canonical WNT signaling pathway. Genetically, the secreted protein Dickkopf (Dkk) family is known as an antagonist to the WNT. To clarify the role of DKK1 in the WNT signaling pathway in the colorectal carcinogenesis, we examined the DKK1 promoter methylation in CRC and analyze the relationship of expression level of DKK1 and MYC in relation with APC gene abnormalities. Methods: We integrated clinico-pathological and molecular findings of 41 cases of CRC. We adopted methylation-specific PCR, DNA sequencing, allelic loss analysis, quantitative RT-PCR, and MSI testing for genetic analyses. Results: CRCs with DKK1 promotor methylation were found in 10 cases (24.4%), which were located predominantly in the proximal colon and frequently showed findings of poorly differentiated adenocarcinoma or mucinous adenocarcinoma. Furthermore, colorectal cancers with DKK1 promotor methylation showed characteristics of microsatellite instability (MSI)-high (70%) and a BRAF mutation (40%), which are known as the CpG island methylator phenotype (CIMP). In the DKK1 promotor methylation group, the relative expression level of DKK1 mRNA was significantly reduced in comparison to the DKK1 promotor un-methylation group (p MYC expression in the DKK1 promotor methylation group was significantly elevated compared to that in the DKK1 promotor un-methylation group (p Conclusions: It is suggested that DKK1 is one of the regulators involved in MYC expression through the WNT signaling pathway and may have a negative effect on carcinogenesis of the colorectum without APC abnormalities.
    VL  - 6
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Division of Genetic Medicine, Master of Science, Graduate School of Science and Engineering Research, Kindai University, Higashiosaka, Japan

  • Division of Genetic Medicine, Master of Science, Graduate School of Science and Engineering Research, Kindai University, Higashiosaka, Japan

  • Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan

  • Sections